Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
True to form, you still don't answer the question...
lasers,
So with the volunteer recruitment announcement, can we assume that the FDA has already approved ELTP's protocol for the efficacy trial?
Thanks,
MJ
AJ,
I couldn't have done it without your help providing me with the content.
MJ
senderos,
Last year, the ELTP annual shareholder's meeting was held on May 21st. So I would assume it will convene sometime in May this year.
MJ
I'd say that you need to contact your Representative in Congress and demand that he/she crack the whip at the FDA...
Straight from the FDA's article:
Not too shabby... ELTP/Nasrat Hakim met with Dr. Sharon Hertz, FDA's Deputy Director of the Division of Anesthesia, Analgesia and Addiction Products [ http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm269645.htm ]
ELTP Conference Call - Nasrat Hakim:
ELTP might have to add Facilities D, E, F, G, H, I, J and K in order to keep up with the manufacturing of the agonist for ELI 201, 202, 216, 400, 500, 501, 600 and 601. Not to mention a massive expansion of the blending Facility C.
ELTP's 10Q is out... Let's get more questions added to the Q&A List for tomorrow's CC:
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
f. Would the FDA allow ELTP to HAL trial multiple products together?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. Epic Agreement
a. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
b. Are there any numbers yet on sales of Isradpine?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12. Since a lot of positive changes with Elite, will Elite be doing another evaluation of company worth?
13.
ELTP's 10-Q is out on Edgar Online:
http://yahoo.brand.edgar-online.com/default.aspx?cik=1053369
If the 10Q conjures up questions for tomorrow's CC, add them to the Q&A List:
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
f. Would the FDA allow ELTP to HAL trial multiple products together?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. Epic Agreement
a. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
b. Are there any numbers yet on sales of Isradpine?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12. Since a lot of positive changes with Elite, will Elite be doing another evaluation of company worth?
13.
The following metrics regarding the distribution of SA's ELTP article are provided at the bottom of the article:
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
f. Would the FDA allow ELTP to HAL trial multiple products together?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. Epic Agreement
a. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
b. Are there any numbers yet on sales of Isradpine?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12. Since a lot of positive changes with Elite, will Elite be doing another evaluation of company worth?
Like the one done Fall/Winter 2013.
13.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
f. Would the FDA allow ELTP to HAL trial multiple products together?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. Epic Agreement
a. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
b. Are there any numbers yet on sales of Isradpine?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12. Since a lot of positive changes with Elite, will Elite be doing another evaluation of company worth?
Like the one done Fall/Winter 2013.
Maz,
Concerns have been raised previously on this board about giving ELTP management an advance copy of the CC question list... That it might foster prepared/canned answers. Since this is a public forum/board, it's not like ELTP couldn't get the information anyway. So I don't have a problem e-mailing the question list to Diane beforehand if there is a consensus amongst us about doing so.
Regarding prioritizing the questions, I think it would be difficult to arrive at an agreed to priority list... Especially since the list is dynamic/changing with questions potentially getting added up until the CC.
Since callers are limited to asking one question, it would insure more of the questions would get answered if we had more people participating in the Q&A session. I encourage all my fellow investors to do so.
MJ
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
f. Would the FDA allow ELTP to HAL trial multiple products together?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12.
**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are typically allowed to ask one question following ELTP management’s opening statements. To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
(Copy/paste the latest posted list and add your question(s) at the end of the list)
1. Clinical Trials
a. When can we expect Lifetree abuse liability results?
b. How long do you expect these trials to last?
c. How many products are tested at a time in these studies?
d. Is the plan to file upon successful results?
e. Is it possible to get the data in the form of a Pie Chart to help a layperson understand the actual trial results?
2. Lincoln Park Capital (LPC) Securities Funding
a. How many have been placed with LPC exclusive of the free shares?
b. How much money was generated for the shares?
c. How much of the money has been spent?
d. What was it used on?
3. Any plans for Eli-154?
4. Updates on Eli-201 and Eli 202?
5. What's going on with the three drugs in Scale up?
6. Any generics moving up the ladder to commercialization?
7. Given the share price hovering at the “worst case” scenario, and far below the 2.10-2.75 levels that were indicated as the more reasonable valuation range at that time, why are you comfortable with the valuation as reflective of Elite’s future?
8. I understand we had an agreement with Epic for 8 drugs where we get a 15% profit split. I also understand that we are no longer proceeding with the last 7 drugs. However, the first and only drug has been filed with the FDA for 3 1/2 years now and we haven't heard anything. Do you have any updates on this?
9. Eli 200
a. Any FDA feedback?
b. Update on NDA ART filing progess.
c. Zogenix just got their ADT Zohydro approved without an efficacy trial. Do you think this zohydro decision will have any bearing on Elite's ELI 200 requiring an efficacy trial?
10. Status update on the arbitration of Phentermine with Precision Dose?
11. Eli 216
a. Given that Elite's generic NDA ART line takes less time and money to bring to market then Elite's once daily Eli 216 product, can you speak to what the current plans are for this product say for instance to partner a combo Eli 201 and 216 together and how quickly you are planning to move forward with this product as there is no other once daily abuse resistant product on the market?
b. What was the reason(s) for not beginning the Eli 216 trials in March 2014?
12.
Fellow ELTP Investors,
With ELTP's Quarterly Financials filing soon, I'd like to facilitate the collection of shareholder questions for the February 17th Conference Call Q&A session with ELTP management. For those who have not participated in the Q&A session before, I'll repeat the purpose/intent of putting together a question list. Callers who participate in the Q&A session are typically limited to asking one question. We’ve got some very knowledgeable ELTP shareholders here on iHub who are well versed in the pharmaceutical arena and have the expertise to provide excellent questions. But they may not be able to participate in the Conference Call or, if they do partake, will only be allotted one question to ask. That’s where the less knowledgeable of us, such as myself, come in… By referring to the Conference Call Question List, we can collectively get most, if not all, of the questions asked.
I will kickoff the Q&A list off with leftover questions from November’s Conference Call that were either not asked or are still relevant for updates. I have also added a few new questions that were recently suggested on this Board. Please note that my role is NOT to censor or editorialize submitted questions. If you have an opinion on what should or should not be asked at the Q&A, then please voice it via a public post on this board. Of course, it's ultimately each callers' prerogative as to what they choose to ask with their allotted question.
With that being said, the Conference Call Question list will follow in a subsequent post.
MJ
Looks like there are potential questions brewing already for the upcoming Conference Call. Soon, I will again facilitate a question list for folks to reference if they wish to partake in the Q&A session.
Stay tuned...
MJ
Received e-mail response from Clay Trader regarding my request for an ELTP chart analysis:
"I plan on doing one."
This should bring even more public exposure for ELTP, which is a good thing!
MJ
I would venture to say that the direction the share price takes depends on ELTP management carrying out its business plan. On that score, I'd say we are in very good shape!
MJ
Lots of eyes/action on ELTP Board.... It's currently #9 on iHub's Top 10 Active Stock Market Forums.
With the recent meteoric rise in ELTP's share price, I thought it would beneficial to hear what Clay Trader thinks about it. So I e-mailed him a request do another one of his chart analysis. Stay tuned...
MJ
Kudos to the posters and my fellow Board Moderators who chose their posts as Stickies. The ELTP Board's current Sticky list is a treasure trove of information for potential investors, not to mention, new and old shareholders alike.
MJ
$.23 is hit right out of the gate!!! Something is brewing. Maybe it's the Seeking Alpha article or there's news out today..... Or both!!!
We think alike... I Stickied it a couple of minutes ago.
Skipper,
Nasrat has no control over the share price other than to execute the business plan, which he has done admirably since taking the helm of the USS Elite Pharmaceuticals. Now it's full steam ahead for filing ELTP's first abuse deterrent opiod NDA for ELI-200!
MJ
I can see it now... Dozens of limos lined up outside the Bellagio to offload the arriving ELTP shareholders. There's a big ruckus in hotel lobby where Couch, Hike, lasers, no2koolaid and NASADQ2020 are arguing over who gets to stay in the Presidential Suite.
MJ
I had the opportunity to meet and chat with Ashok Nigalaye and Ram Potti at ELTP's Annual Shareholders meeting this past Summer. Both had nothing but high praises for Nasrat Hakim... They coined his arrival at ELTP as a "game changer". It's no surprise that Ashok is adding to his already significant ELTP holdings. Just like Nasrat, he's a billionaire in the making. For me, ELTP's success will mean an early and very comfortable retirement.
MJ
no2koolaid,
Well said... Another outstanding post! It's a nice belated Christmas present.
MJ
Moose,
Could you please provide the URL/link to David Ando's article...
Thanks,
MJ
I agree... Couch's post is now my Stickee!
MJ
Gman,
I had the pleasure of meeting Nasrat Hakim at the annual shareholder's meeting this past Summer. I was very impressed by his passion and drive. I also had the opportunity to chat with Ram Potti of Epic Pharm who told me that having Nasrat take the helm of ELTP was a game changer.
I have the utmost confidence in Hakim's expertise to execute ELTP's business plan. So much so, that I recently rolled a portion of my 401k into an IRA trading account and added significantly to my position in ELTP.
2015 promises to be an exciting year for ELTP. I wish all my fellow shareholders a very Merry Christmas and Happy New Year!!!
MJ
Dr T.
Congratulations on your new arrival!...
Now let's see if Santa Hakim brings us a terrific Christmas present like some good news about ELTP's NDA filing.
MJ
I agree that this was a banner year, too... Just imagine what your portfolio will look like next year with ELTP ART product(s) approved to go to market... $970,000 will look like chump change compared to the $3-4 million your portfolio could reach. Calling 2015 a banner year would then be quite an understatement.
sharpei,
If I may beg to differ... No2koolaid's posts on this board wax eloquently and are a treat to read. No editorializing is needed...
MJ
In the November Conference Call, Nasrat also said:
"...We have developed and are pursuing different sales and marketing models and that’s one of the reasons I am on the West Coast...."
Not so sad really... The volume traded so far today is chump change... Hardly a frenzy of selling going on.